Currently, several mAbs against the NaPi2b have been generated, including the humanized antibodies XMT-1536 (https://www.mersana.com/pipeline/xmt-1536/) and XMT-1592 (https://www.mersana.com/pipeline/xmt-1592/), which are undergoing clinical trials for the treatment of ovarian and lung cancers. The gene discussed is SLC34A2; the disease is lung cancer.